Antisense drug discovery and development technology considered in a pharmacological context

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• The terms "antisense" and "siRNA" historically described distinct oligonucleotide structures and mechanisms.
• Medicinal chemistry advancements for ASOs paved the way for siRNA technology, highlighting shared chemical foundations.
• Both ASOs and siRNAs are single-stranded or double-stranded oligonucleotides used therapeutically, targeting RNA for gene silencing.

Purpose of the Study:

• To place antisense oligonucleotides (ASOs) within a pharmacological context.
• To compare the pharmacological behavior of ASOs with that of small interfering RNAs (siRNAs).
• To elucidate the commonalities and differences between ASO and siRNA therapeutic approaches.

Main Methods:

• Review of existing literature on ASO and siRNA medicinal chemistry, pharmacology, and therapeutic applications.
• Comparative analysis of oligonucleotide structures, mechanisms of action, and pharmacokinetic properties.
• Examination of delivery routes and challenges associated with ASO and siRNA therapeutics.

Main Results:

• ASOs and siRNAs share common chemical foundations and can both engage Ago2 for RNA cleavage.
• Significant differences exist in their pharmacokinetic profiles, influencing potential delivery routes.
• ASOs offer diverse post-RNA binding mechanisms, whereas siRNAs rely exclusively on Ago2 activity.

Conclusions:

• ASOs and siRNAs, despite differences, are both crucial therapeutic nucleic acid modalities.
• Understanding their distinct pharmacological profiles is essential for optimizing their use in medicine.
• Further research into optimizing delivery and mechanisms for both ASOs and siRNAs will advance nucleic acid therapeutics.